A Nation Divided: Supreme Court Weighs Bayer's Bid to Shut Down 100,000 Roundup Cancer Lawsuits

 

 A Nation Divided: Supreme Court Weighs Bayer's Bid to Shut Down 100,000 Roundup Cancer Lawsuits

**Subtitle:** *The justices appeared split during oral arguments Monday, with billions of dollars and the fate of thousands of plaintiffs hanging in the balance. A ruling by June could reshape product liability in America.*

**Reading Time:** 8 Minutes | **Category:** Law & Public Health

## Introduction: The Man Who Was the 'Spray Guy'

For more than two decades, John Durnell was the "spray guy" for his neighborhood association in a historic St. Louis neighborhood. Without protective equipment, he walked the local parks, killing weeds with Roundup, the iconic weedkiller that has become a household name across America .

In 2019, Durnell was diagnosed with a rare and often aggressive form of non-Hodgkin lymphoma — cancer of the white blood cells. He blamed Roundup. He sued .

In 2023, a Missouri jury awarded him $1.25 million .

Now, Durnell's case has become the vehicle for one of the most consequential corporate liability battles in a generation. On Monday, April 27, the U.S. Supreme Court heard oral arguments in *Durnell v. Monsanto*, a dispute that could determine whether Bayer is shielded from over 100,000 similar lawsuits accusing the company of failing to warn that its blockbuster herbicide causes cancer .

The atmosphere inside the courtroom was tense. Outside, protesters held signs reading "Stop poisoning the US" . And the justices themselves appeared deeply split, grappling with a question that has no easy answer: When the federal government says a product is safe, can state courts and juries still hold the manufacturer liable?

The stakes could hardly be higher. A ruling in Bayer's favor would "largely bring the Roundup litigation to an end," the company has said, potentially wiping out tens of thousands of claims and saving the German pharmaceutical giant billions . A ruling against Bayer would keep the courthouse doors open — and leave the company facing an ongoing torrent of lawsuits that have already cost it more than $10 billion .

This deep-dive will unpack the legal battle at the heart of the case, the ideological split among the justices, and the human toll behind the statistics. We'll also break down the proposed $7.25 billion settlement, the Trump administration's controversial backing of Bayer, and what this all means for the future of federal regulation and corporate accountability in America.

> **The Bottom Line Up Front:** The Supreme Court is weighing whether federal pesticide law (FIFRA) "preempts" state failure-to-warn claims. Bayer argues that EPA approval of Roundup's label without a cancer warning should immunize it from lawsuits. Plaintiffs argue that state tort law provides a crucial safety net when federal regulation lags behind science. A ruling is expected by late June .

## Part 1: The Legal Showdown – FIFRA vs. The 50 States

At the heart of the case is a dry-sounding federal statute with enormous real-world consequences: the **Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)** .

FIFRA governs the sale and labeling of pesticides in the United States. The Environmental Protection Agency (EPA) is responsible for registering pesticides and approving their labels. Crucially, the law bars states from imposing "differing or additional requirements" — an attempt to create national uniformity in pesticide regulation .

Bayer's argument is elegant in its simplicity: The EPA has repeatedly reviewed glyphosate, Roundup's active ingredient, and found that it does *not* cause cancer. The agency has repeatedly approved Roundup's label *without* a cancer warning. Therefore, Bayer argues, it would be irrational — and illegal — to allow a jury in Missouri to second-guess that expert federal judgment by imposing a warning the EPA says isn't necessary .

"There was no inconsistency between the label and EPA requirements and no basis to deem the label false or misleading," Bayer told the court in its filings. "That should end the case."

**Paul Clement**, a legendary Supreme Court advocate who has argued hundreds of cases, made Bayer's pitch to the justices on Monday. Clement warned that allowing state lawsuits to proceed would create a chaotic "patchwork" of conflicting standards across the country.

"A Missouri jury imposed a cancer-warning requirement that EPA does not require. That additional requirement is preempted," Clement said .

He echoed a concern raised by **Justice Brett Kavanaugh**, who pressed the plaintiffs on the uniformity problem: "You think it's uniformity when each state can require different things? The label subjects you to liability in one state and does not subject you to liability in the other state. Is that uniformity?" 

### The Plaintiffs' Counterargument

Ashley Keller, the attorney representing Durnell (and, by extension, over 100,000 other plaintiffs), offered a forceful rebuttal. He argued that FIFRA does *not* immunize pesticide manufacturers from state tort law. The label must be "adequate," and a label is "misbranded" — and thus illegal — if it fails to warn of known risks .

Keller emphasized a simple but powerful point: federal approval is "not a safe harbor" .

"Regardless of what the EPA says, they are not a safe harbor," Keller told the justices. "Though I think there are a lot of conscientious people working at that agency, I think we should also all agree that things slip through the cracks with that agency" .

His argument found a sympathetic ear in **Chief Justice John Roberts**. Roberts probed whether state lawsuits can serve as a "faster way of reacting to changing information" about a product's safety, rather than waiting for the often-slower federal regulatory process to catch up .

"In other words, it's not necessarily the case that they're doing something inconsistent with what the EPA would do," Roberts said. "It's simply a fact that they're responsive to the new information more quickly than the federal government is" .

### The Gorsuch Question

Perhaps the most pointed exchange came from **Justice Neil Gorsuch**, a conservative often skeptical of expansive federal power. Gorsuch pressed Bayer's Clement on a seeming inconsistency in the company's logic.

"If supposing that EPA can bring a claim against you for misbranding and seek criminal and civil penalties despite a properly registered item, how would it be inconsistent with FIFRA to allow state tort suits to do the same thing?" Gorsuch asked .

Gorsuch also wondered aloud: if a state can determine that a product is so hazardous that it must be **banned** within its borders, why can't it allow its residents to **sue** over alleged harms? 

That line of questioning suggests that even some of the court's conservatives are wrestling with the limits of Bayer's preemption argument.

### The Circuit Split

The Supreme Court agreed to hear this case in part because lower federal courts are deeply divided on this very question. The U.S. Court of Appeals for the Third Circuit sided with Bayer, ruling that FIFRA preempts state failure-to-warn claims. But the Ninth and Eleventh Circuits reached the opposite conclusion, allowing similar lawsuits to proceed .

This "circuit split" is precisely the kind of legal chaos the Supreme Court exists to resolve. A ruling for Bayer would align with the Third Circuit and effectively kill the vast majority of Roundup cases nationwide. A ruling for Durnell would align with the Ninth and Eleventh Circuits, keeping the litigation alive and kicking — and sending a signal that the courthouse doors remain open.

## Part 2: The Human Cost – The Faces Behind the 100,000 Claims

Behind the legal jargon and the corporate balance sheets are real people. Real pain. Real families.

John Durnell is the named plaintiff, but he represents a class of over 100,000 individuals who have filed cases alleging a link between Roundup and non-Hodgkin lymphoma, a cancer of the immune system . The World Health Organization's International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" in 2015 — a finding Bayer disputes, citing decades of studies and regulatory approvals showing the product is safe .

Durnell used Roundup for about 20 years, beginning in 1996. He was the "spray guy" for his neighborhood association in St. Louis, killing weeds at local parks without protective gear. He was diagnosed with non-Hodgkin lymphoma in 2019 .

His case went to trial in Missouri state court. In 2023, a jury found that Monsanto (which Bayer acquired in 2018) had failed to warn users of the dangers associated with Roundup and glyphosate. The jury awarded Durnell $1.25 million — a fraction of the multi-billion dollar verdicts that have been handed down in other cases, but a significant victory nonetheless .

A state appeals court upheld that verdict in 2025. Now, the case is before the nation's highest court .

### Protests Outside the Courtroom

On Monday, as the justices heard arguments inside, protesters gathered on the sidewalk in front of the Supreme Court building. Among them were Linda and Jon Martin, retirees from southern California. They held a sign reading "Stop poisoning the US" .

Both said they are Trump supporters and were "very disappointed" that the Trump administration is backing Bayer in the case.

"Just because the EPA says something, doesn't mean it's always the truth," Linda Martin said .

"If they're fighting to get rid of liability, they know they must be liable," Jon Martin added .

Their presence was a reminder that while the legal battle is about statutory interpretation and preemption doctrine, the human stakes are about illness, loss, and the search for accountability.

### The Plaintiffs Who Won't Settle

Bayer has proposed a $7.25 billion class-action settlement to resolve tens of thousands of current and future lawsuits. But claimants have until early June to decide whether to opt out . The settlement requires "something approaching zero" opt-outs to be successful, CEO Bill Anderson has said .

Some plaintiffs have already indicated they will reject the deal. They want their day in court. They want a jury to hear their story. And they want Bayer to pay.

A Reuters/Ipsos poll released last week highlighted the political risks for the Trump administration in backing Bayer. According to the poll, **63% of respondents** said they oppose protecting companies from lawsuits when they sell cancer-causing products, even if the company warns about the risk .

That's a striking number — and a reminder that while preemption is a legal doctrine, it is also a deeply unpopular one.

## Part 3: The $7.25 Billion Settlement – A Sword Hanging Over the Case

While the justices were hearing arguments, a parallel process was unfolding in a Missouri courtroom.

A federal judge has preliminarily approved a proposed **$7.25 billion class-action settlement** that Bayer hopes will resolve the vast majority of Roundup lawsuits — regardless of how the Supreme Court rules .

The deal, announced in February 2026, would set up a compensation fund for tens of thousands of claimants who allege they developed non-Hodgkin lymphoma after using Roundup. Payments are expected to vary based on the plaintiff's age, illness severity, and other factors. Those with less aggressive forms of non-Hodgkin lymphoma could receive around $40,000; those with more severe cases could receive up to $160,000 .

Critically, the settlement requires near-universal participation. Claimants have until **June 4, 2026** to decide whether to opt out . If too many plaintiffs reject the deal, it could collapse — and Bayer would be left to face the litigation wave alone.

**CEO Bill Anderson** has been candid about the stakes. "The opt-outs need to be something approaching zero," he said on a March investor call. "If people opt out, then you don't really have an agreement, and then we would have to move on to other potential solutions" .

Bayer's "other potential solutions" include a Supreme Court victory. If the justices rule for Bayer, the company's legal exposure would be dramatically reduced — and the settlement offer would become far less generous. That's why the settlement timeline is so closely intertwined with the court's calendar. A ruling is expected by late June . The opt-out deadline is June 4.

### The Financial Picture

The litigation has been a drag on Bayer's finances since its $63 billion acquisition of Monsanto in 2018. The company has already spent more than $10 billion defending and settling Roundup cases .

In its latest securities filings, Bayer reserved **$11.25 billion (€9.6 billion)** to deal with approximately 65,000 outstanding suits . The company expects free cash flow to be negative this year — between negative €1.5 billion and negative €2.5 billion — due to settlement-related payouts .

Bayer's stock fell about 3.4% on Monday, reflecting investor uncertainty about the outcome . Yet the shares are up more than 70% over the past 12 months, suggesting that the market is cautiously optimistic that the company's multipronged strategy — Supreme Court victory, settlement approval, and lobbying of state legislatures — will eventually contain the litigation .

## Part 4: The Trump Administration's Role – Politics at the Podium

One of the most striking features of the case is the stance of the **Trump administration**. The Justice Department has filed a brief in support of Bayer, and Deputy Solicitor General **Sarah Harris** argued alongside Bayer's counsel on Monday .

The administration's argument mirrors Bayer's: "EPA registers pesticides only if EPA approves their labels as adequate to protect health. Federal law then requires manufacturers to keep using that label" .

Harris warned the justices about the chaos of a state-by-state patchwork of labeling requirements.

"If you had 50 different states that are just like jumping the gun — Iowa says maybe this causes cancer, California says absolutely causes cancer, some other state says this doesn't cause cancer at all, so put that on your label too — it completely undermines the uniformity of the labeling," Harris said .

**Chief Justice Roberts** pushed back, however, questioning whether states have any legal recourse if new information of harm comes to light while federal regulators are still deliberating.

"Throughout that long process, in response to information that suggests there is a risk that's not on the label, the states cannot do anything?" Roberts asked .

Harris acknowledged the concern but reiterated that Congress intended FIFRA to create a uniform national system — and that the proper avenue for challenging EPA decisions is through the federal regulatory process, not through state tort lawsuits.

The administration's position has put it at odds with public opinion, as the Reuters/Ipsos poll demonstrated. And it has alienated some of Trump's own supporters, like the Martins protesting outside the courthouse.

But the administration is betting that its legal arguments will carry the day — and that a Supreme Court victory for Bayer will be seen as a win for "regulatory certainty" and "American farmers," not as a giveaway to a foreign corporation.

### President Trump's Personal Involvement

President Trump has separately pushed to protect glyphosate, the active ingredient in Roundup, and moved in February to ramp up domestic production . His administration has made clear that it views the widespread availability of glyphosate-based herbicides as essential to American agriculture.

In its brief, the administration warned that allowing state lawsuits to proceed could threaten the nation's food supply. Bayer has echoed that warning, saying that the lawsuits could force it to stop supplying glyphosate to U.S. farmers — a outcome it described as a "devastating risk to America's food supply" .

## Part 5: The Stakes for Farmers, Business, and American Law

The implications of the case extend far beyond Bayer and Roundup.

### The Agricultural Sector

Major agricultural groups have filed briefs in support of Bayer, warning that a ruling against the company could jeopardize access to essential crop protection tools. Farmers rely on glyphosate-based herbicides to control weeds and maximize yields. If the litigation forces Bayer to pull the product from the market — or if the threat of liability causes other pesticide manufacturers to abandon the U.S. market — the consequences for the food supply could be severe .

"Major agricultural groups warn that would pose a 'devastating risk to America's food supply,'" USA Today reported .

### The Business Community

The U.S. Chamber of Commerce and other business groups are watching the case closely. They argue that the same preemption principles at issue here govern other industries regulated by federal law — including medical devices, cosmetics, and food .

A ruling for Bayer would strengthen federal preemption across the board, making it harder for plaintiffs to bring state-law claims against manufacturers whose products are regulated by federal agencies. A ruling for Durnell would weaken preemption, opening the door to more state-court litigation.

### The Precedent for Federal Regulation

The case could reshape the balance of power between federal agencies and state courts in product liability law. If the Supreme Court rules that EPA approval of a label immunizes a manufacturer from failure-to-warn claims, it would effectively transfer enormous power to federal regulators — and away from juries.

**University of Richmond law professor Carl Tobias** offered a cautionary note, however. Even if the Supreme Court rules for Bayer on the failure-to-warn issue, it won't wipe out all the cases. Plaintiffs could still pursue claims for negligence, defective design, and other theories of liability .

"There will still be other claims left in cases, for negligence and defective design, that will be unaffected if failure-to-warn goes away," Tobias said. "I don't see any maneuver that can wipe all the cases out. That's pretty much mission impossible" .

Tobias's point is important. A Bayer victory would be a significant blow to the plaintiffs' bar, but it would not be a death blow. The litigation would continue, albeit on a narrower and potentially more manageable scale.

## Frequently Asked Questions (FAQ)

**Q: What is the specific legal question before the Supreme Court?**

A: The Court is deciding whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) "preempts" — or overrides — state-law failure-to-warn claims against pesticide manufacturers. In plain English: if the EPA approved Roundup's label without a cancer warning, can a state jury still require Monsanto to pay damages for not putting that warning on the label? 

**Q: Who is John Durnell?**

A: Durnell is a Missouri man who used Roundup as the "spray guy" for his neighborhood association for about 20 years, without protective equipment. He was diagnosed with non-Hodgkin lymphoma in 2019, sued Monsanto, and won a $1.25 million jury verdict in 2023. His case is now before the Supreme Court .

**Q: How many Roundup lawsuits are there?**

A: More than 100,000 plaintiffs have filed cases in U.S. state and federal courts alleging a link between Roundup and cancer. Bayer has already spent more than $10 billion on litigation since acquiring Monsanto in 2018 .

**Q: What is the proposed $7.25 billion settlement?**

A: Bayer has proposed a class-action settlement that would resolve tens of thousands of current and future claims. Claimants have until June 4, 2026, to decide whether to participate. The settlement requires near-universal participation to take effect .

**Q: What side is the Trump administration on?**

A: The Trump administration is backing Bayer. The Justice Department filed a brief in support of the company and argued alongside Bayer's counsel on Monday, arguing that FIFRA preempts state failure-to-warn claims .

**Q: What happens if Bayer wins?**

A: A ruling for Bayer would "largely bring the Roundup litigation to an end," the company has said. Thousands of cases could be dismissed. However, plaintiffs could still pursue other legal theories, such as negligence or defective design .

**Q: What happens if Durnell wins?**

A: A ruling for Durnell would allow the Roundup litigation to continue. Bayer would remain exposed to billions of dollars in potential liability, and the proposed $7.25 billion settlement might collapse if claimants decide to hold out for better terms .

**Q: When will the Supreme Court rule?**

A: A ruling is expected by the end of June 2026 — potentially within days of the June 4 settlement opt-out deadline .

## Conclusion: Justice in the Balance

We started this article with a man. John Durnell, the "spray guy" from St. Louis, who spent two decades walking his neighborhood parks without protective gear, unaware that the product in his hand might be making him sick.

We end with the nine justices of the Supreme Court, wrestling with a question that has no easy answer.

**Chief Justice Roberts** worried that state lawsuits might be necessary to provide a "faster way of reacting to new information" than the federal regulatory process allows .

**Justice Kavanaugh** worried that a patchwork of state standards would undermine the uniformity that Congress intended when it enacted FIFRA .

**Justice Gorsuch** wondered why a state can ban a product but can't allow its citizens to sue over it .

**Justice Kagan** pressed the plaintiffs on how state lawsuits could be squared with Congress's preemptive intent .

The Court is genuinely divided. The arguments revealed no clear majority for either side. The eventual ruling — expected in late June — could be close, perhaps 5-4, with the conservative justices splintering along unexpected lines.

### For the Plaintiffs:

The Court's decision will determine whether you have a legal remedy — or whether the courthouse doors are closed to you. A ruling for Bayer would be devastating. It would mean that federal approval trumps state accountability, and that corporate immunity — at least for failure-to-warn claims — is the law of the land.

### For Bayer:

The Court's decision will determine whether the company can finally put the Roundup litigation behind it — or whether the legal cloud will hang over its stock price for years to come. A ruling for Durnell would be a major setback, potentially costing the company tens of billions of dollars more.

### For the American Public:

The Court's decision will shape the balance of power between federal regulators and state courts — and between corporate interests and individual rights — for decades to come. It will signal whether the EPA's approval is the final word on product safety, or whether juries can have the last word.

### The Bottom Line:

The Supreme Court is weighing whether a product the EPA says is safe can be the basis for billion-dollar liability in state court. It is a question with profound implications — for Bayer, for the 100,000 plaintiffs, and for the future of product liability law in America.

The justices are split. The outcome is uncertain. And everyone is waiting.

A ruling is expected by the end of June. Until then, the Roundup litigation — and the fate of John Durnell and 100,000 others — hangs in the balance.

---

**#SupremeCourt #Roundup #Bayer #Glyphosate #ProductLiability #FIFRA #Law #Cancer**

---

*Disclaimer: This article is for informational purposes only. It does not constitute legal advice. The Supreme Court has not yet ruled in this case. Individuals with specific legal questions should consult a licensed attorney.*